Cytokinetics to Announce First Quarter Results on April 28, 2016
April 14 2016 - 4:00PM
Cytokinetics, Inc. (Nasdaq:CYTK) announced today that it is
scheduled to report first quarter results on Thursday, April 28,
2016 at 4:00 PM Eastern Time. Following the announcement,
Cytokinetics’ senior management will host a conference call at 4:30
PM Eastern Time to discuss operational and financial results and
the company’s outlook for the future.
The conference call will be simultaneously webcast and can be
accessed from the homepage and in the Investors & Media section
of Cytokinetics’ website at www.cytokinetics.com. The live audio of
the conference call can also be accessed by telephone by dialing
either (866) 999-CYTK (2985) (United States and Canada) or (706)
679-3078 (international) and typing in the passcode 29638364.
An archived replay of the webcast will be available via
Cytokinetics' website until May 5, 2016. The replay will also
be available via telephone by dialing (855) 859-2056 (United States
and Canada) or (404) 537-3406 (international) and typing in the
passcode 29638364 from April 28, 2016 at 5:30 PM Eastern Time until
May 5, 2016.
About Cytokinetics
Cytokinetics is a late-stage biopharmaceutical company focused
on discovering, developing and commercializing first-in-class
muscle activators as potential treatments for debilitating diseases
in which muscle performance is compromised and/or declining. With
an unmatched understanding of muscle biology and the mechanics of
muscle performance, the company is developing small molecule drug
candidates specifically engineered to increase muscle function and
contractility. Cytokinetics’ lead drug candidate is tirasemtiv, a
fast skeletal muscle activator, for the potential treatment of
ALS. Tirasemtiv has been granted orphan drug designation and
fast track status by the U.S. Food and Drug Administration and
orphan medicinal product designation by the European Medicines
Agency for the potential treatment of ALS. Cytokinetics holds
the exclusive right to develop and commercialize tirasemtiv.
Cytokinetics is collaborating with Amgen Inc. to develop omecamtiv
mecarbil, a novel cardiac muscle activator, for the potential
treatment of heart failure. Cytokinetics is collaborating with
Astellas Pharma Inc. to develop CK-2127107, a fast skeletal muscle
activator, for the potential treatment of spinal muscular atrophy.
Amgen holds an exclusive license worldwide to develop and
commercialize omecamtiv mecarbil and Astellas holds an exclusive
license worldwide to develop and commercialize CK-2127107. Both
licenses are subject to Cytokinetics’ specified development and
commercialization participation rights. For additional
information about Cytokinetics, visit www.cytokinetics.com.
This press release contains forward-looking statements for
purposes of the Private Securities Litigation Reform Act of 1995
(the “Act”). Cytokinetics disclaims any intent or obligation to
update these forward-looking statements, and claims the protection
of the Act’s safe harbor for forward-looking statements. Examples
of such statements include, but are not limited to, statements
relating to planned presentations, and the properties and potential
benefits of Cytokinetics’ drug candidates and potential drug
candidates. Such statements are based on management’s current
expectations, but actual results may differ materially due to
various risks and uncertainties, including, but not limited to,
potential difficulties or delays in the development, testing,
regulatory approval and production of Cytokinetics' drug candidates
and potential drug candidates that could slow or prevent clinical
development or product approval, including risks that current and
past results of clinical trials or preclinical studies may not be
indicative of future clinical trials results and that Cytokinetics'
drug candidates and potential drug candidates may have unexpected
adverse side effects or inadequate therapeutic efficacy. For
further information regarding these and other risks related to
Cytokinetics’ business, investors should consult Cytokinetics’
filings with the Securities and Exchange Commission.
Contact:
Cytokinetics
Diane Weiser
Vice President, Corporate Communications, Investor Relations
(650) 624-3060
Cytokinetics (NASDAQ:CYTK)
Historical Stock Chart
From Aug 2024 to Sep 2024
Cytokinetics (NASDAQ:CYTK)
Historical Stock Chart
From Sep 2023 to Sep 2024